Drug Search Results
More Filters [+]

AERAS-456

Alternative Names: aeras-456, aeras456, aeras 456
Latest Update: 2019-12-19
Latest Update Note: Clinical Trial Update

Product Description

contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01865487)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Aeras
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AERAS-456

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Latent Tuberculosis

Phase 1: Latent Tuberculosis|Tuberculosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

C-037-456

P1

Completed

Tuberculosis

2016-06-24

C-035-456

P2

Completed

Latent Tuberculosis

2015-08-01

C-032-456

P1

Completed

Latent Tuberculosis

2012-12-01

Recent News Events

Date

Type

Title